Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule belonging to the class of dichlorobenzenes and pyrimidine derivatives. It is listed as an experimental drug in DrugBank with no approved therapeutic use or detailed pharmacological background available. The structure suggests it may act as a kinase inhibitor, potentially targeting cyclin-dependent kinase 2 (CDK2), which plays a key role in cell cycle regulation and DNA replication. However, there are no clinical indications or marketed uses reported for this compound[1][3][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2R)-1-[4-({4-[(2,5-dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol.